Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Jan 19, 2018- Results of tumor response assessments by blinded independent imaging review using both mRECIST and RECIST v1.1 criteria to be presented today at the Gastrointestinal Cancers Symposium
Eisai Inc. announced today results from the independent imaging review (IIR) of the REFLECT study (Study 304), a Phase 3 trial evaluating lenvatinib (marketed as Lenvima®), the company's multiple...
-
Jan 9, 2018
Eisai Co., Ltd. and Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that they received Breakthrough Therapy Designation from the U.S. Food and Drug...
-
Dec 8, 2017- Results of this combination study were presented in a Spotlight Session (Spotlight Session 6: PD6-13) on December 7
Eisai Inc. today announced updated results of ENHANCE 1, a Phase 1b/2 trial investigating eribulin mesylate (marketed as HALAVEN®, "eribulin"), in combination with the Merck & Co., Inc.,...
-
Dec 6, 2017seizures and healthcare utilization associated with perampanel therapy
Eisai Inc. presented eight posters on perampanel (marketed as FYCOMPA® CIII) at the American Epilepsy Society (AES) Annual Meeting in Washington, D.C. The poster presentations included analyses...
Dec 5, 2017Tools now available to help adolescents with epilepsy transition to the adult health care system underscoring Eisai's leadership and commitment to the epilepsy communityThe Child Neurology Foundation (CNF) and Eisai today announced the availability of original resources aimed at helping those living with epilepsy navigate and simplify the transition from their...
-
Nov 22, 2017Data of note includes post-hoc analysis identifying potential predictors of major response to treatment with perampanel
Eisai Inc. announced today the presentation of eight posters on data, including real-world use of perampanel (marketed as FYCOMPA® CIII). These data will be presented at the American Epilepsy...
-
Oct 30, 2017
Eisai Inc. announced today the presentation of three posters during the 10th annual Clinical Trials on Alzheimer's Disease (CTAD) meeting, highlighting data on innovative ways to screen for...
-
Oct 3, 2017
Eisai Inc., the U.S. pharmaceutical subsidiary of Tokyo, Japan-based Eisai Co., Ltd., today announced that it has signed an agreement with Grupo Biotoscana (GBT) granting GBT the exclusive...
-
Sep 26, 2017- Lenvatinib, if approved, would be the first new systemic treatment for first-line use in patients with liver cancer in more than a decade
Eisai Inc. today announced the U.S. Food and Drug Administration (FDA) accepted for review a supplemental New Drug Application (sNDA) for lenvatinib (marketed as Lenvima®) for the potential use...
Sep 25, 2017Eisai Inc., the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., today announced the immediate appointment of Michael Amoroso as Senior Vice President, Americas Commercial, Oncology...
-
Sep 10, 2017- Updated results of advanced RCC cohort from Study 111 support continued investigation of first-line use of the combination in ongoing Phase 3 CLEAR study
Eisai Inc. today announced interim results from the advanced renal cell carcinoma (RCC) cohort of Study 111, a Phase 1b/2 study investigating lenvatinib (marketed as Lenvima® in the U.S. and...
-
Sep 10, 2017- Quality of life findings follow presentation of positive results at ASCO 2017 in which lenvatinib was the first systemic therapy to demonstrate non-inferiority to sorafenib in overall survival in first-line treatment of patients with unresectable HCC
Eisai Inc. announced today a delay in the deterioration of five health-related quality of life domains that affect patients' daily lives was observed in patients treated with lenvatinib as...
-
Aug 31, 2017- New data in metastatic renal cell carcinoma from Study 111 evaluating lenvatinib in combination with pembrolizumab to be presented in a proffered paper session on Saturday, Sept. 9 at 10:15 a.m. CEST
Eisai Inc. will present data from its lenvatinib (marketed as Lenvima®) clinical trial program in four difficult-to-treat cancers at the European Society of Medical Oncology (ESMO) 2017 Congress...
-
Aug 28, 2017First kinase inhibitor to show improvement in overall survival in any patient group with RAI-R DTC
Eisai Inc. announced data from a prespecified subgroup analysis, which was published in the Journal of Clinical Oncology, showing treatment with lenvatinib (marketed as Lenvima®) resulted in a...
-
Jul 26, 2017- First antiepileptic drug (AED) to apply FDA's regulatory pathway of extrapolation for monotherapy use; FDA proposed using this pathway to get monotherapy options to patients sooner
Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved the company's supplemental New Drug Application (sNDA) for FYCOMPA® (perampanel) CIII as monotherapy use...
-
Jul 25, 2017- Filing based on positive pivotal Phase 3 trial demonstrating non-inferior overall survival compared to sorafenib
Eisai Inc. today announced it submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for the first-line use of lenvatinib (marketed as Lenvima®), the...
-
Jul 17, 2017
Eisai Inc. announced today the presentation of eight posters, including safety data on three different compounds in its Alzheimer's disease portfolio, at the Alzheimer's Association International...
-
Jun 21, 2017Lorcaserin Phase IIIb/IV Outcomes Study Assesses Incidence of Major Adverse Cardiovascular Events (MACE) in Patients with Overweight or Obesity
Eisai Inc. today announced that the ongoing investigational CAMELLIA-TIMI 61 study of lorcaserin (marketed as BELVIQ® CIV) will continue as planned, based on the recommendation of an independent...
-
Jun 4, 2017- Lenvatinib is the first systemic therapy to demonstrate non-inferiority to sorafenib in the primary efficacy endpoint of overall survival
Eisai Inc. today announced results from the REFLECT study (Study 304), a Phase 3 trial evaluating lenvatinib (marketed as Lenvima®), the company's multiple receptor tyrosine kinase inhibitor...
-
Jun 3, 2017- Interim results of first evaluable cohort (metastatic endometrial cancer) of Study 111, the Phase 1b/2 trial evaluating lenvatinib in combination with pembrolizumab in selected solid tumors, to be presented at 2017 ASCO Annual Meeting
Eisai Inc. today announced interim results from the first evaluable cohort of Study 111, a Phase 1b/2 study investigating lenvatinib (marketed as Lenvima®), a multiple receptor tyrosine kinase...
-
May 31, 2017
Eisai Inc., the U.S. pharmaceutical subsidiary of Tokyo, Japan-based Eisai Co., Ltd., and Johns Hopkins University announced today that they have extended their drug discovery collaboration...
-
May 30, 2017
Eisai Inc., the U.S. subsidiary of Tokyo, Japan-based Eisai Co., Ltd., announced today that it has entered into a new joint research agreement with the Broad Institute, a collaborative research...
-
May 18, 2017- Full results of Study 304, a Phase 3 study evaluating the safety and efficacy of Lenvima® (lenvatinib) as compared to sorafenib in the first-line treatment of patients with unresectable hepatocellular carcinoma, to be presented in an oral presentation on Sunday, June 4 at 8:12 a.m. CDT
Eisai Inc. announced today the presentation of new data and analyses at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting from June 3 – 7 in Chicago. The data to be presented...
-
Apr 27, 2017Data to be Presented at the American Academy of Neurology "Best Of" Epilepsy Session
Eisai Inc. announced today the presentation of results from a new meta-analysis of published clinical trials showing that the effect of adjunctive antiepileptic drug (AED) treatment versus placebo...
-
Apr 19, 20175-YEAR ANNIVERSARY OF LONDON DECLARATION ON NEGLECTED TROPICAL DISEASES
Eisai Inc. announced today that its parent company Tokyo, Japan-based Eisai Co., Ltd. has pledged the continuing support of its initiatives for the elimination of lymphatic filariasis (LF), a...
-
Apr 13, 2017Eisai Announces Perampanel Data in Epilepsy at the 2017 American Academy of Neurology Annual MeetingMeta-analysis on the extrapolation of adult antiepileptic drug efficacy data, including perampanel, to pediatric patients to be featured in "Best Of" oral presentation panel
Eisai Inc. announced today that eight poster presentations featuring data on the safety and efficacy of perampanel (marketed as FYCOMPA® CIII) in a range of seizure types will be presented at the...
-
Mar 28, 2017Research to be presented spans four of the Company's investigational and marketed oncology therapies, both as single agents and in combination
Eisai Inc. announced today 13 presentations of clinical and preclinical research at the American Association for Cancer Research (AACR) 2017 Annual Meeting, April 1 – 5, 2017 in Washington, D.C....
Mar 23, 2017Eisai Inc. is pleased to announce that it will be launching the latest "Medikidz Explain Epilepsy," book as part of their participation at the Epilepsy Foundation's National Walk for Epilepsy on...
Mar 17, 2017Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced the immediate appointment of Kirk Shepard, MD, as Senior Vice President, Global Medical Affairs of the Oncology...
-
Jan 25, 2017
Eisai Inc. today announced positive topline results from the randomized, multicenter Phase 3 trial (Study 304) evaluating the company's multiple receptor tyrosine kinase inhibitor, lenvatinib...
Jan 18, 2017Accelerating Access to Health Care in Low and Lower-Middle Income CountriesEisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announced today that it is participating in Access Accelerated, a global partnership to advance access to non-communicable...
- Jan 4, 2017
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd. (collectively, "Eisai"), announced today that it has reached an agreement with Arena Pharmaceuticals, Inc. to revise the November...
- Dec 19, 2016
Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that Eisai Laboratórios Ltda., a subsidiary of Eisai Inc., has received regulatory approval from the Brazilian Health...
Dec 12, 2016Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announced today the presentation of two posters highlighting the latest data on elenbecestat (development code: E2609), its...
-
Dec 12, 2016
Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai Inc. today announced new interim data investigating Merck's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in...
- Dec 5, 2016Presentations Include Analysis of Real-World Use and Post-Hoc Analysis of Long-Term Safety and Efficacy
Eisai Inc. announced today new analyses and data on perampanel presented at the 2016 Annual Meeting of the American Epilepsy Society (AES). Perampanel, marketed as FYCOMPA® CIII, is indicated as...
- Dec 5, 2016
Eisai Inc. announced today final results of its Phase 3 open-label two-year study of rufinamide, which were presented at the 2016 Annual Meeting of the American Epilepsy Society (AES) held from...
- Dec 1, 2016
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced the immediate appointment of Rebecca Jolley as Senior Vice President Americas Commercial, Oncology Business...
-
Nov 30, 2016
Eisai Inc. announced today the presentation of new data from studies of eribulin, marketed under the brand name Halaven®, at the 2016 San Antonio Breast Cancer Symposium (SABCS). Two ongoing...
- Nov 28, 2016
Eisai Inc. announced today the presentation of 12 posters during the 70th annual American Epilepsy Society (AES) Annual Meeting, highlighting data from the company's anti-epileptic drugs FYCOMPA®...
-
Nov 17, 2016
Eisai Inc. announced today that it has received U.S. Food and Drug Administration (FDA) Fast Track designation for the development of E2609, a Beta-secretase Cleaving Enzyme (BACE) inhibitor...
- Nov 3, 2016
Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today the presentation of one oral presentation and one poster at Obesity Week(SM) regarding new data on BELVIQ® (lorcaserin...
-
Oct 31, 2016
Eisai Inc. and Purdue Pharma L.P. announced today the initiation of a multi-center, randomized Phase 2 clinical study (Study 202) to evaluate Eisai's internally-discovered oral dual orexin...
- Oct 31, 2016
Eisai Inc. announced today that enrollment has begun in the U.S. for MISSIONAD, a Phase 3 clinical program for E2609, a Beta-secretase Cleaving Enzyme (BACE) inhibitor for patients with early...
- Oct 28, 2016Trials to assess perampanel in those with Lennox-Gastaut Syndrome, a rare form of epilepsy, and in children with partial-onset seizures now enrolling patients
Eisai Inc. announced today the initiation of two multi-center, global Phase 3 clinical trials assessing FYCOMPA® (perampanel) CIII in two different patient populations: patients age 2 years and...
-
Oct 26, 2016Two other Eisai-marketed products -- HALAVEN® (eribulin mesylate) and BELVIQ® (lorcaserin HCI) CIV -- also collect nominations
Eisai Inc. announced today that LENVIMA® (lenvatinib), the company's multiple receptor tyrosine kinase inhibitor (TKI), has been nominated for Best Pharmaceutical Product at the 10th Annual Prix...
- Oct 26, 2016"Medikidz Explain LGS," endorsed by leading advocacy groups, educates public on rare and severe form of epilepsy
Eisai Inc. today announced the launch of "Medikidz Explain Lennox-Gastaut Syndrome (LGS)," an educational comic book designed to inform people about LGS, a rare type of epilepsy that is usually...
- Oct 26, 2016
Eisai Inc. and the Oklahoma Medical Research Foundation (OMRF) have formed a research collaboration to study the autoimmune disease lupus. Under the new agreement, Eisai's research team at its...
-
Oct 13, 2016Study Evaluated Maximum Tolerated Dose
Eisai Inc. announced today the presentation of preliminary results of a Phase 1b clinical study (Study 111) of its in-house developed multiple receptor tyrosine kinase inhibitor lenvatinib...
- Oct 3, 2016New FDA-Approved Formulation Offers Patients a Once-Daily Dosing Option for Chronic Weight Management
Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced the availability of BELVIQ XR® (lorcaserin HCl) CIV extended-release 20 mg tablets, a new once-daily dosing option that...
-
Sep 29, 2016
Eisai Inc. announced today the presentation of seven abstracts featuring data on its cancer treatments at the European Society of Medical Oncology (ESMO) 2016 Congress. The abstracts highlight new...
-
Sep 29, 2016Eisai's CLEAR study will compare the company's multiple receptor TKI, lenvatinib, plus the anti-PD-1 pembrolizumab and lenvatinib plus the mTOR inhibitor everolimus versus sunitinib, the current standard of care in this setting
Eisai Inc. announced today the initiation of a multicenter, global, randomized Phase 3 study that will evaluate the efficacy and safety of two regimens containing Eisai's multiple receptor...
- Sep 26, 2016Application Based on New FDA Communication Supporting Use as Monotherapy for the Treatment of Partial Onset Seizures Based on Extrapolation
Eisai Inc. announced today that it has submitted a supplemental application to the U.S. Food and Drug Administration (FDA) for a proposed label change for its antiepileptic drug FYCOMPA®...
-
Sep 22, 2016METAvivor and Eisai Inc. Partner to Urge MBC Community to Discuss Living with Their Diagnosis, How They Draw Strength and Encouragement from Their Support Networks
"The cancer has spread. We can offer you treatment, but ultimately, it is incurable." A metastatic breast cancer (MBC) diagnosis comes with many medical, practical and emotional challenges as...
- Sep 21, 2016The Light of Life Foundation, ThyCa: Thyroid Cancer Survivors' Association, and Eisai Team Up to Increase Awareness by Urging People with Thyroid Cancer to Share their Experiences
A thyroid cancer diagnosis can lead to significant distress as patients and caregivers cope with various medical, emotional and economic challenges, as survivors, patients and caregivers have...
-
Sep 21, 2016
Eisai Inc. announced today the presentation of abstracts at the 86th Annual Meeting of the American Thyroid Association (ATA) that highlight an investigational Phase 2 trial currently recruiting...
- Sep 15, 2016Discovery innovation unit of 90 scientists at dedicated research facility to use human genetics and related data to develop novel, targeted medicines for dementia and oncology
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., has announced the launch of the Eisai Andover innovative Medicines (AiM) Institute, a discovery innovation unit within the...
- Sep 14, 2016
Eisai Inc. today announced that new data presented at the 12th European Congress on Epileptology (ECE) showed that long-term adjunctive use of FYCOMPA® (perampanel) CIII for up to two and a half...
- Jul 28, 2016Child Neurology Foundation Initiative Provides Guidance for Pediatric Neurology Patients
The Child Neurology Foundation (CNF) announced today that a consensus statement addressing the role of the neurologist in transitioning children to the adult healthcare system has been published...
Jul 19, 2016Once-a-Day Tablet Offers Millions of Americans a New Option to Address Chronic Weight ManagementEisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for BELVIQ XR® (lorcaserin...
- Jul 14, 2016Eisai and Arena Pharmaceuticals Announce Regulatory Approval of VENESPRI® (lorcaserin HCl) in MexicoFirst Country in Latin America to Approve lorcaserin
Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that the Federal Commission for the Protection Against Sanitary Risk (COFEPRIS) has granted regulatory approval of the...
- Jun 29, 2016Eisai Highlights its Strong Pipeline and Innovative Approach to R&D at Company's U.S. Scientific Day-- "Ricchi" philosophy focuses on hardest-to-treat medical conditions, including dementia
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today held a Scientific Day to present its approach to global R&D and introduce the company's robust neurology and oncology...
- Jun 22, 2016
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announced today that it will host a Scientific Day on June 29, 2016 from 9:00 a.m. EDT to 12:45 p.m. EDT in New York City, and...
- Jun 15, 2016New FDA-Approved Formulation Indicated as Adjunctive Therapy for the Treatment of Partial-Onset Seizures and Primary Generalized Tonic-Clonic Seizures
Eisai Inc. announced today the availability of FYCOMPA® (perampanel) Oral Suspension, a new bioequivalent interchangeable alternative to the FYCOMPA tablet for patients who have difficulty...
- Jun 14, 2016Two-day forum conducted to identify innovative resources that may help patients with rare, severe form of epilepsy
Eisai Inc. and the Lennox-Gastaut Syndrome (LGS) Foundation held a hackathon event, called #HackLGS, bringing together LGS caregivers, technology developers, students and creative specialists on...
-
Jun 2, 2016Combination treatment recently approved by FDA for Patients with Advanced Renal Cell Carcinoma Following Prior Anti-angiogenic Therapy
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., and Novartis Pharmaceuticals Corporation, an affiliate of Basel, Switzerland-based Novartis AG, have entered into an agreement to...
-
May 24, 2016- Abstracts include sub-analysis from second pivotal trial of Halaven® to show overall survival advantage, which supported January FDA approval in advanced liposarcoma
Eisai Inc. announced today presentations of new analyses of studies supporting U.S. Food and Drug Administration (FDA) approvals at the 2016 American Society of Clinical Oncology (ASCO) Annual...
- May 24, 2016
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced the immediate appointment of Maria Garrigan, as Vice President, Global Regulatory Strategy for the Oncology...
-
May 13, 2016- Near-tripling in progression-free survival demonstrated by LENVIMA and everolimus when compared with a standard of care advances treatment paradigm in this category
Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) approved LENVIMA® (lenvatinib), the company's multiple receptor tyrosine kinase inhibitor, in combination with...
- May 2, 2016New Formulation Expands Treatment Options for Epilepsy Patients with POS and PGTC Seizures
Eisai Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved FYCOMPA® (perampanel) CIII Oral Suspension as adjunctive therapy for the treatment of partial-onset...
- Apr 20, 2016
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced the immediate appointment of Avinash Desai, MD, as Vice President, Americas Oncology Medical Affairs for the...
Apr 14, 2016Fourth Comic Book in the Series “Medikidz Explain Epilepsy” Launching at the 2016 National Walk for Epilepsy in Washington, D.C.-
Apr 11, 2016
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced the immediate appointment of Beyhan Zaim as Vice President Commercial Development & Alzheimer's Disease Global...
- Apr 6, 2016
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced the immediate appointment of Paul Hawthorne to the position of Senior Vice President, U.S. Commercial, Neurology...
-
Mar 18, 2016--Helsinn Therapeutics Inc. to obtain all rights to promote and distribute AKYNZEO® (netupitant/palonosetron) --
Helsinn, the Swiss pharmaceutical Group focused on building quality cancer care, and Eisai Inc., the U.S. pharmaceutical subsidiary of the research-based human healthcare company Eisai Co., Ltd ,...
-
Feb 10, 2016Pivotal Data Led to Recent FDA Approval for This Indication
Eisai Inc. announced today that results from its pivotal Phase 3 study (Study 309) investigating the use of Halaven® (eribulin mesylate) Injection (0.5 mg per mL) in certain types of soft tissue...
-
Jan 29, 2016- Halaven is the first and only single agent to prolong overall survival in patients with previously treated advanced (unresectable or metastatic) liposarcoma in a Phase 3 trial
Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) approved Halaven® (eribulin mesylate) Injection (0.5 mg per mL) for the treatment of patients with unresectable or...
-
Jan 17, 2016Supplemental application based on progression-free survival data from Study 205, a three-arm Phase 2 study comparing lenvatinib in combination with everolimus, everolimus alone and lenvatinib alone in these patients
Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for lenvatinib for the potential treatment...
-
Dec 9, 2015
Halozyme Therapeutics, Inc. (NASDAQ: HALO) and Eisai Inc. will present a scientific poster entitled, "Pegylated Recombinant Human Hyaluronidase PH20 (PEGPH20) Enhances Efficacy of Eribulin...
- Dec 2, 2015
Eisai Inc. announced today that 21 posters highlighting perampanel data and an interim analysis from the first and largest caregiver burden study in epilepsy will be presented at the 69th Annual...
-
Dec 1, 2015Long-Term, Large-Scale Outcomes Study Assesses Cardiovascular and Metabolic Effects of BELVIQ in Overweight and Obese Patients
Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that the CAMELLIA-TIMI 61 study has reached its target enrollment of 12,000 patients at more than 470 sites in eight...
-
Nov 30, 2015
Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for an extended...
- Nov 18, 2015Clinical Study (MORAb-009-201) of the Safety and Efficacy of Amatuximab in Combination with Pemetrexed and Cisplatin in Subjects with Unresectable Malignant Pleural Mesothelioma (MPM)
Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it has enrolled the first patient in the randomized, double-blind ARTEMIS—Amatuximab Research in Treatment-naïve Epithelial...
- Nov 17, 2015
Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it entered into an agreement with the Targeted Alpha Therapy Group (TAT Group) at the University of Gothenburg in Sweden to...
-
Nov 13, 2015
Helsinn Group and Eisai Inc. announced today that the American Society of Clinical Oncology (ASCO) has published a focused update to its clinical practice guidelines for antiemetics in oncology...
- Nov 9, 2015
Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it has entered into a license agreement with Blaze Bioscience, Inc. of Seattle, WA, a privately held biotechnology company...
-
Nov 4, 2015The parties hope to develop new cancer targets and novel therapeutic approaches
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced it has initiated a research collaboration for research and development with the Paoli Calmettes Institute (IPC),...
- Oct 26, 2015
Eisai Inc. announced today that Halaven® (eribulin mesylate) Injection has been nominated by the Galien Foundation within the category, "Best Pharmaceutical Agent of the Year" at the ninth annual...
- Oct 26, 2015
Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it has presented preclinical data showing the immunosuppressive effects of the CA125 tumor antigen on the investigational...
-
Oct 19, 2015Findings suggest need for improved dialogue between patients receiving chemotherapy and their healthcare team, including pharmacists
-
Oct 16, 2015
Results from an investigational Phase 2 clinical trial evaluating lenvatinib in combination with everolimus and lenvatinib and everolimus alone for the treatment of metastatic renal cell carcinoma...
-
Oct 15, 2015
Eisai Inc. announced today the presentation of a company-record seven abstracts at the 15th International Thyroid Congress (ITC), highlighting the importance of the Phase 3 SELECT trial of...
-
Oct 8, 2015
Eisai Inc. announced the decision of the National Comprehensive Cancer Network® (NCCN®) to recommend LENVIMA™ (lenvatinib) as the preferred agent for the treatment of patients with progressive...
- Sep 28, 2015
Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for eribulin mesylate (eribulin) being evaluated...
- Sep 24, 2015Eisai, CancerCare®, Cancer Support Community®, Cornucopia Cancer Support Center™ and Meals on Wheels America Continue their Commitment to Providing Meal Assistance to Enable Loved Ones to Spend More Quality Time Together
Magnolia Meals at Home®, a program that delivers nutritious meals at no-cost to patients living with breast cancer and their families, is now helping those living with thyroid cancer. Sponsored...
- Sep 14, 2015
Eisai Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company's New Drug Application (NDA) for FYCOMPA® (perampanel) CIII Oral Suspension 0.5...
-
Aug 31, 2015Companies to develop lemborexant for the potential treatment of insomnia and explore other future indications
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., and Purdue Pharma L.P. announced today that they have entered into a worldwide collaboration agreement for the development and...
- Aug 24, 2015Global Multicenter Study of FYCOMPA as Adjunctive Therapy Published in Neurology
Eisai Inc. announced today that the results of its Phase 3 trial (Study 332) for FYCOMPA® (perampanel) CIII have been published in the online edition of Neurology, the medical journal of the...
-
Jul 31, 2015Clinical trial will explore whether or not eribulin in combination with PEGPH20 can improve overall response rate in women with advanced breast cancer
Eisai Inc. announced today that its parent company Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO: Haruo Naito, "Eisai") and Halozyme Therapeutics, Inc. (Headquarters: San Diego,...
-
Jul 30, 2015
Eisai Inc. announced today that regulatory applications were submitted simultaneously in the United States, European Union and Japan (to the FDA, EMA and MHLW, respectively) for eribulin, for the...
